Email updates

Keep up to date with the latest news and content from Pediatric Rheumatology and BioMed Central.

This article is part of the supplement: 15th Paediatric Rheumatology European Society (PreS) Congress

Open Access Poster presentation

Diagnostic value and clinical significance of antibodies against a modified citrullinated vimentin (anti-MCV) in patients with early juvenile arthritis

SO Salugina1*, ES Fedorov1, EN Alexandrova1, AA Novikov1, MV Cherkasova1, AA Baranov2, YA Valogina2, TN Nikolaeva2 and NA Zubova2

  • * Corresponding author: SO Salugina

Author Affiliations

1 Institute of Rheumatology RAMS, Moscow, Russian Federation

2 Department of Clinical Pathology, Yaroslavl Medical Academy, Yaroslavl, Russian Federation

For all author emails, please log on.

Pediatric Rheumatology 2008, 6(Suppl 1):P9  doi:10.1186/1546-0096-6-S1-P9


The electronic version of this article is the complete one and can be found online at: http://www.ped-rheum.com/content/6/S1/P9


Published:15 September 2008

© 2008 Salugina et al; licensee BioMed Central Ltd.

Objective

To investigate the diagnostic value and clinical significance of anti-MCV in pts with early JA.

Patients and methods: 85 pts were included in the study (M/F = 36/49) in the age of 1,5–16 years (mean 8.7 ± 4.9 years). Systemic JA – 10 pts (11.8%), poly – 37 (43.5%), oligo-38 (44.7%). Duration of disease was < 6 months. We studied also 54 pts with early RA, 28 pts with undifferentiated arthritis (UA) and 14 healthy children. Anti-MCV was measured in serum by enzyme-linked immunosorbent assay (ELISA) using the cut off value of 25 U/ml. IgM RF and hsCRP-by laser-nephelometry assay on BN-100 analyser.

Results

Anti-MCV levels were elevated in 23 (27.1%) pts with early JA, in systemic – 2 (20%), poly – 11(29.7%), oligo-10 (26.3%). In pts with RF positive JA – 5 (100%), in RF negative pts- 7(17.1%) (p < 0.001). In the control groups: 34/54 (62.9%) adults with early RA (p < 0,001), 14/28 (50%) with UA (p < 0.05), none of the healthy children showed anti-MCV positivity. The median anti-MCV level in JA was 16.8 U/ml (IR: 11.5–26.4), in RF+ pts (M-834.9; IR 539.3–1149.3 U/ml) was higher than in RF-pts (M-14.5; IR:5.7–22.0 U/ml) (p < 0.001). Anti-MCV correlated with parameters of disease activity (hs CRP, ESR), with RF and anti-CCP positivity. Anti-MCV were not associated with ANA.

Conclusion

Determination of anti-MCV levels especially together with RF and anti-CCP in pts with early JA can indicate evolution JRA similar RA in adults. Anti-MCV levels correlated with common parameters of inflammation and acute phase response and may be useful to monitor disease activity.